Recently, sirtuins (SIRT1–7) have demonstrated a great potential as biomarkers and/or targets for the treatment of BCs and the dual role of SIRT1–7 as tumor promoters or suppressors in BCs have been widely discussed [41]. This evidence concerns the gene SIRT1 and neoplasm.